Skip to main content

Podocon 25

Generic: Podophyllum resin

Verified·Apr 23, 2026
Manufacturer
Padagis
NDC
72162-1117
Route
TOPICAL
ICD-10 indication
A63.0

Affordability Check

How much will you actually pay for Podocon 25?

In 30 seconds, see every legitimate way to afford Podocon 25 — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Podocon 25

What is this medication?

Podocon 25 is a prescription topical solution primarily used for the medical treatment of external genital and perianal warts, which are caused by certain types of the human papillomavirus. The active ingredient is podophyllum resin, a substance derived from the roots of the mandrake plant. This medication acts as a cytotoxic agent that works by arresting the division of cells within the wart tissue, leading to the eventual necrosis and shedding of the growth over time.

Because of its potent and potentially caustic properties, this medication must be applied only by a healthcare professional in a clinical environment and is not intended for home use. During the procedure, the provider applies the solution directly to the wart while protecting the surrounding healthy skin with a protective barrier like petroleum jelly. Patients are usually required to wash the treated area with soap and water several hours after application to minimize the risk of severe irritation or systemic toxicity.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Podocon 25. Official source: DailyMed (NLM) · Label effective Dec 24, 2024

Indications and usage
INDICATIONS: Podocon-25 ® (25% podophyllin in benzoin tincture) is indicated for the removal of soft genital (venereal) warts (condylomata acuminata) (4) .
Dosage and administration
DOSAGE AND ADMINISTRATION: PODOCON-25 ® IS TO BE APPLIED ONLY BY A PHYSICIAN. IT IS NOT TO BE DISPENSED TO THE PATIENT. SHAKE WELL. Thoroughly cleanse affected area. Use supplied applicator to apply Podocon-25 ® sparingly to lesion. Avoid contact with healthy tissue. Allow to dry thoroughly. Only intact (no bleeding) lesions should be treated. As podophyllin is a powerful caustic and severe irritant, it is recommended the first application of Podocon-25 ® be left in contact for only a short time (30-40 minutes) to determine patient’s sensitivity. To avoid systemic absorption, time of contact should be minimum time necessary to produce the desired result (1 to 4 hours, depending on condition of lesion and of patient), the physician developing his/her own experience and technique. Large areas or numerous warts should not be treated at once. After treatment time has elapsed, remove dried Podocon-25 ® thoroughly with alcohol or soap and water.
Contraindications
CONTRAINDICATIONS: Podocon-25 ® is contraindicated in diabetics, patients using steroids or with poor blood circulation. Podocon-25 ® should not be used on bleeding warts, moles, birthmarks or unusual warts with hair growing from them. It is recommended that Podocon-25 ® not be used during pregnancy (see Pregnancy warning below).
Warnings
WARNINGS: Podophyllin is a powerful caustic and severe irritant. Keep away from the eyes; if eye contact occurs, flush with copious amounts of warm water and consult physician or poison control center immediately for advice.
Adverse reactions
ADVERSE REACTIONS: The use of topical podophyllin has been known to result in paresthesia, polyneuritis, paralytic ileus, pyrexia, leukopenia, thrombocytopenia, coma and death (5) . Pregnancy: There have been reports of complications associated with the topical use of podophyllin on condylomata of pregnant patients including birth defects, fetal death and stillbirth (6) . In the absence of controlled safety studies, podophyllin remains contraindicated for use on pregnant patients. Nursing Mothers: It is not known whether podophyllin is excreted in human milk following topical application. In the absence of controlled safety studies, podophyllin remains contraindicated for use on nursing patients.
Use in pregnancy
Pregnancy: There have been reports of complications associated with the topical use of podophyllin on condylomata of pregnant patients including birth defects, fetal death and stillbirth (6) . In the absence of controlled safety studies, podophyllin remains contraindicated for use on pregnant patients.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.